2. Goldschneider J., Gotschlich E.C., Artenstein M.S. Human immunity to meningococci. I. The role of humoral antibodies. J. Exp. Med. 1969; 129: 1307–26.

3. Artenstein M.S., Gold R., Zimmerly J.G., Schneider Y., Harkins Ch. Prevention of meningococcal disease by group C polysaccharide. N. Engl. J. Med. 1969; 272: 417–20.

4. Kostyukova N.N., Bekhalo V.A. [Current meningococcal vaccines: advantages and disadvantages and new challenges]. Epidemiologiуa i vakcinoprophylactica 2016; (4): 64–73 (In Russ.).

5. Platonov A.E., Kharit S.V., Platonova O.K. [Vaccine prevention of meningococcal infection in the world and in Russia]. Epidemiologiya i vakcinoprophylactika 2009; (5): 32–46. (In Russ.).

6. Kostyukova N.N., Bakhaev Yu.P., Belomestnykh E.L., Duplistcheva V.A.,, Kirpichnikova E.N., Kuzmin Yu.K., Lamazhaa А.М., Lunochkina М.А., Mazurenko М.К., Oyun D.N. et al. [The trial of mass vaccine prophylaxis of meningococcal infection among the children. In: Acute meningitis. Collection of proceedings]. Moscow, 1982; 31–7. (In Russ.).

7. Chernysheva T.F., Skirda T.A., Chistyakova O.R., Koroleva I.S. [Vaccine prevention of meningococcal disease]. Epidemiologiya i vakcinoprophylactika 2003; (3): 44–6. (In Russ.).

8. Kolesnikov A.V., Kozyr A.V., Schemyakin I.G., Dyatlov I.A. [Contemporary conception of immune response activation mechanism by conjugated polysaccharide vaccines.] Zhurnal Microbiologii, Epidemiologii i Immunobiologii 2015; (3): 97–106 (In Russ.).

9. World Health Organization. Meningococcal meningitis. Emergency preparations and response. 2018. http/www.who.int/csr/disease/meningococcal/en

10. Trotter C.L., Maiden М.C.J. Meningococcal vaccine and herd immunity: lessons, learned from serogroup conjugate vaccination programmes. Expert. Rev. Vaccines 2009; 8(7): 851–61.

11. Ishola D.A., Borrow R., Findlow H., Findlow J., Trotter C.L., Ramsay M. Prevalent of serum bactericidal antibodies to serogroup C Neisseria meningitidis in England a decade after vaccine introduction. Clin. Vaccine. Immunol. 2012; 19(8): 1126–30.

12. Borrow R. Advances with vaccination against Neisseria meningitidis. Trop. Med. Intern. Health 2012; 17(12): 1478–91.

13. Borrow R, Alarcon P., Carlos J., Caugant D., Christensen H., Deblag R. et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev. Vaccines 2017; 16(4): 313–28.

14. Maurice J. Vaccine storage threatens spread of meningococcus in Niger. Lancet 2015; 385: 2241.

15. Daugla D.M., Garni J.P., Gamougam K., Naibei N., Mbainnadji L., Narbe M. et al. Effect of serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study. Lancet 2014; 383: 40–7.

16. Novak R.T., Kambou J.L., Diomande F.V., Tarbangdo T.F., Quedrado-Fraore K., Sangare et al. Segroup A meningococcal conjugate vaccination in Burkina-Faso: analysis of national surveillance data. Lancet Infect. Dis. 2012; (12): 354–63.

17. Collard J.M., Issaka B., Zaneidou M., Higonnet S., Nicolas P. Taha M.-Kh. Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination. BMC Infect. Dis. 2013; 13: 576.

18. Kristiansen P.A., KuBa A., Quedraogo F.-S., Salam J., Quedraogo R., Sangare L., Diomande F. еt al. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac. BMC Infect. Dis. 2014; 14: 663.

19. Stuart J.M. Impact of serogroup A meningococcal conjugate vaccine in Africa. Human Vaccines & Immunutherapeutics 2018. https://doi.org/10.1080/216455.2017.1412022

20. Koroleva M.A., Mironov K.O., Koroleva I.S. [Epidemiological characteristics of generalized meningococcal infection caused by Neisseria meningitidis serogroup W in the world and the Russian Federalation]. Èpidemiologiâ i infekcionnye bolezni. Аktual’nye voprosy 2018; (3): 16–23. (In Russ.).

21. Frota A.C.C., Millagres L.G., Harrison L.M, Ferreira B., Barroto D.M., Pereira G.S. et al. Immunogenisity and safety of meningococcal conjugate vaccine in schoolchildren and teenagers infected and uninfected with HIV in Rio-de-Janeiro, Brasilia. Pediatr. Infect. Dis. J. 2015; 34(51): E113–8.

22. Kostinov M.P., Tarasova A.A, [Vaccination of children with hemoblastisis]. Epidemiologiya i vakcinoprophylactika 2017; (1): 76–7. (In Russ.).

23. Fierbig T., Bertri F., Freiberger F., Pinto V., Claus H., Romano M.R. et al. Functional expression of the capsule polymerase of Neisseria meningitidis serogroup X: a new perspective for vaccine development. Glycobiology 2014; 24(2): 150–8.

24. Tonneato D., Pizza M., Mazignani V., Rappuoli R. Emerging experience with meningicoccal serogroup B protein vaccines. Expert. Rev. Vaccines 2017; 16(5): 433–51.

25. Tan L.K.K., Carlone G.M., Borrow R. Advances in the development vaccines against Neisseria meningitidis. N. Engl. J. Med. 2010; 362(16): 1511–20.

26. Nadel S. Prospects for eradication of meningococcal disease. Arch. Dis. Child. 2012; 97: 993–8.

27. Pizza M., Scarlato V., Masignani V., Frico B., Comanucci M., Jenings G.F. et al. Identification of vaccine candidate against serogroup B meningococcus by whole-genome sequesing. Science 2009; 287(5459): 1816–20.

28. McIntosh E.X., Carey V., Tonneato D., Dull P., James W. Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals – the example of serogroup B meningococcal infection. Ther. Adv. Vaccines 2015; 3(1): 13–23.

29. RomanovaYu.M., Gintsburg A.L. [Bacterial biofilms as a natural form of existence of bacteria in the environment and host organism]. Zhurnal Mikrobiologii 2011; (3): 99–109. (In Russ.).

30. Caugan D.A., Hoiby E.A., Magnus P., Schneel O., Hoel F., Bjuna G. et al. Asymptomatic carriage of Neisseria meningitidis in randomly sampled population. J. Clin. Microbiol. 1994; 32(2): 323–30.

31. Stephens D. Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 1999; 353: 941–2.

32. Harrison L.H., Shutt K.A., Arnold K.E., Stern E.I., Pondo T. Meningococcal carriage among Georgia and Maryland High school students. J. Infect. Dis. 2015; 2011(11): 1761–8.

33. Christensen H., May M., Bowen J., Hickman M., Trotter C.L. Meningococcal carriage by age: a systematic review. Lancet Infect. Dis. 2010; 10(12): 853–61.

34. Caugant D.A., Maiden M.C.J. Meningococcal carriage and disease – population biology and evolution. Vaccine 2009; 27(4): B64–B70.

35. Mironov K.O., Tagatchenkova T.A., Koroleva I.S., Platonov A.E., Shipulin G.A. [Genetic characteristics of Neisseria meningitidis strains obtained from healthy carriers during meningococcal outbreaks]. Zhurnal Mikrobiologii 2011; (2): 22–7. (In Russ.).

36. Jarvis G.A. Recognition and control of neisserial infections by antibody and complement. Trends Microbiol. 1995; 33: 198–201.

37. Yoshwich K.O., McCaw S.E., Strobel L., Frosсh M., Gray-Owen S.W. Sterilizing immunity elicited by Neisseria meningitidis carriage shows broader protection than predicted by serum antibody-cross reactivity in CEACAM-humanized mice. Infect. Immun. 2015; 83(2): 354–63.

38. Gorlina M.Kh., Kostyukova N.N., Mildzikhova I., Chernysheva T.F., Mishina A.I., Skirda Т.А., Kayhthy H. [Serotypes and subtypes of Neisseria meningitidis, circulating among carriers in Moscow (1989–1991)]. Zhurnal Mikrobiologii 1994; prilozhenie: 44–8. (In Russ.).

39. Jones J.Z., Christodoulides M., Brooks J.L., Miller A.R.O., Cartwright K.A.V., Heckels J.E. Dynamics of carriage in a group of military recruits: subtype stability and specifity of immune response, following colonization. J. Infect. Dis. 1998; 178: 451–9.

40. Horton R.E., Stuart H., Christensen H., Borrow R., Guthrie T., Davenport V. et al. Influence of age and carriage status on salivary IgA to Neisseria meningitidis. Epidemiol. Infect. 2005; 133: 882–9.

41. Davenport V., Guthrie T., Findlow J., Borrow P., Williams N.A., Heyderman R.S. Evidence for naturally acquired T cell-mediated immunity to Neisseria meningitidis by Neisseria meningitidis. J. Immunol. 2003; 171: 4263–70.

42. Nurkka A., MacLennan J., Jantir V., Obaro S., Greenwood B., Käyhthy Y. Salivary antibody response to vaccination with meningococcal A/C polysaccharide vaccine in previously vaccinated and unvaccinated Gambian children. Vaccine 2001; 19(4–5): 547–57.

43. Zang Q., Finn A. Mucosal immunology against pathogenic nasopharyngeal bacteria. J. Clin. Pathol. 2004; 57(10): 1015–25.

44. Read R.C., Baxter D., Hadwick D.R., Faust S.N., FinnA., Gordon St.-B. et al. Effect of quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine on meningococcal carriage: a observer blind phase randomized clinical trail. Lancet 2014; 384: 2123–31.

45. Favorova L.A., Teleshevskaya E.Ya. [Epidemiology and prophylaxis of meningococcal disease]. Sovetskaya Medicina 1971; (11): 113–8. (In Russ.).

46. Breakwell L., Whaley M., Khan U.I., Bandy U., Alexander-Scott N., Dupont L. et al. Meningococcal carriage among university student population – United States, 2015. Vaccine 2018; 36: 29–35.

47. Soeters H.M., Whaley M., Scott N.A., Kanadaniau K.V., MacNeil J.K. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a College-Rhode Island, 2015–2016. Clin. Infect. Dis. 2017; 64(8): 1115–22.

48. McNamara L.А., Thomas J.D., MacNeil D., Chang H.Y., Day M., Fisher E., et al. Meningococcal carriage following a vaccination campaign with MenB-4C and MenB-FHbp in response to a university serogroup B meningococcal disease outbreak – Oregon, 2015–2016. J. Infect. Dis. 2017; 216: 1130–40.

49. Balmer P., Burmen C., SierraL., York L.J. Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature. Human Vaccine & Immunotherapeuetics 2018; (5): 1118–30.

50. Maiden M.C.J., Frosсh M. Can we, should we eradicate the meningococcus? Vaccine 2012; 30(6): 652–6.